Special notice
Notice of Intent to Sole Source MP201 Drug Synthesis
HT9425-24-Q-0095
Defense Health Agency (Dha), Army Med Res Acq Activity. Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology).
Awarded
Mitochon Pharmaceuticals, Inc.
$50,000.00 obligated so far on USAspending
Description
As published on SAM.gov.
The U.S. Army Medical Research Acquisition Activity (USAMRAA) in support of the Walter Reed Army Institute of Research (WRAIR) intends to negotiate solely (as prescribed in FAR 13.106(b)(1)(i)) with Mitochon Pharmaceuticals, 970 Cross Ln, Blue Bell, PA 19422, to provide synthesis of the prodrug of 2,4-dinitrophenol (DNP) called MP201, against ocular dysfunction caused by blast exposure, for WRAIR’s Blast Induced Neurotrauma Branch’s (BINT) study on the efficacy of the drug MP201 by data interpretation/analysis, preparation of quarterly reports, annual progress reports, manuscripts, and final project report..
The MP201 required for this study, is developed and synthesized by Mitochon Pharmaceuticals and is not available through any other source. The North American Industry Classification System (NAICS) for this requirement is 541715 and the size standard is 1000. This announcement constitutes the only notice by the government; a written solicitation will not be issued. All sources that believe they are eligible to provide these items must respond in writing.
Responses must be supported with clear and convincing evidence to clearly articulate the ability to provide the items outlined above. A request for documentation will not be considered an affirmative response. This Special Notice of Intent is not a request for competitive quotes. Information received will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government.
If no written responses are received by the date listed below, the purchase will be awarded without further remark. All questions and responses concerning this notice shall be emailed to Ms. Dawn Jennings at dawn.v.jennings.civ@health.mil. Interested concerns must identify their capability in writing to the above e-mail address or by mail to the address listed below no later than 12:00PM ET, July 26, 2024. Contracting Office Address:
US Army Medical Research Acquisition Activity, ATTN: FCMR-ACO-AA, 808 Schreider Street, Frederick, MD 21702-5014 Point of Contact: Dawn Jennings Dawn.v.jennings.civ@health.mil
The contract, on USAspending
Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.
- Recipient
- Mitochon Pharmaceuticals, Inc.
- UEI
- JGJ7TELAKUY8
- CAGE
- 7NNV1
- Vendor location
- Blue Bell, PA
- Contract
- HT942525P0014, purchase order
- Obligated
- $50,000.00, potential $150,000
- Actions
- 1 between November 7, 2024 and November 7, 2024
- Competition
- Not Competed Under SAP, 1 offer received
- Set-aside reported
- No Set Aside Used.
- Described as
- MP201 Drug Development/Synthesis
- Match
- solicitation number HT942524Q0095 equals the FPDS solicitation identifier; same awarding office HT9425 (high confidence)
- Record
- USAspending award page
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
July 11, 2024
Special notice, originally sources sought
Due July 26, 2024 at 12:00 PM EDT. SAM.gov, notice c9f826b4d9d6476bb38304db1a77dfa1
Points of contact
- Dawn Jenningsdawn.v.jennings.civ@health.mil
Also open from this buyer
- Blanket Purchase Agreement for Medical Gases and Dry IceCombined synopsis and solicitationSmall businessNAICS 325120Silver Spring, MDHT942626QE031Closes in 13 daysOct 1
- COMBINED SYNOPSIS/SOLICITATION for Regulated Medical Waste servicesCombined synopsis and solicitationSmall businessNAICS 562211HT942726RE015Closes in 17 daysOct 5